Osiris, Novartis Pharmaceuticals Corp. deal

The companies will develop therapeutics for tissue regeneration based on human mesenchymal stem cells (MSC). Novartis receives an exclusive

Read the full 194 word article

How to gain access

Continue reading with a
two-week free trial.